- Recipharm has entered a strategic collaboration with Fusix Biotech to support the development and manufacturing of FUSE102, an oncolytic virus-based cancer immunotherapy candidate.
- Under the agreement, Recipharm will support technology transfer, manufacture the Master Virus Seed, and produce GMP clinical material for first-in-human trials.
Recipharm has announced a strategic collaboration with Fusix Biotech to support the development and manufacturing of next-generation cancer immunotherapies based on oncolytic virus technology. The partnership will focus on Fusix Biotech’s lead candidate, FUSE102, as the company advances the program toward clinical development.
Fusix Biotech is developing cancer therapies using its proprietary oncolytic fusion virus technology, which is designed to combine direct tumor cell destruction with modulation of the tumor microenvironment to enhance anti-tumor immune responses. According to the company, FUSE102 is a chimeric oncolytic virus encoding a high-affinity soluble PD-1 intended to enable immune checkpoint inhibition and strengthen anti-tumor activity.
Under the collaboration, Recipharm will conduct a technology transfer of the FUSE102 process to support clinical development. Building on its capabilities in viral vectors and advanced biologics manufacturing, the CDMO will manufacture the Master Virus Seed and GMP clinical material for first-in-human trials. The initial process development work will be carried out through Recipharm’s collaboration with iBET.
“Oncolytic viruses represent one of the most promising areas in cancer immunotherapy today. We are pleased to collaborate with Fusix Biotech to help advance this innovative platform toward the clinic.”
Greg Behar, CEO of Recipharm
The collaboration adds to Recipharm’s contract manufacturing and development activities in oncology biologics. The company said its services span viral vectors, oncolytic viruses, nucleic acids, recombinant proteins, and sterile fill-finish operations, alongside analytical development, process optimization, and regulatory support for programs progressing from early development through commercial manufacture.
